Skip to main content
Equibles
EBRCZ logo

EBRCZ · EBR Systems, Inc. · Metrics

Track EBRCZ — free

Use EBRCZ with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research EBRCZ.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.11 At close · Oct 15
Rebalance outlook locked
Going-concern doubt — flagged Aug 11, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on the Company's cash, cash equivalents, and marketable securities as of June 30, 2026, and its expectation to generate operating losses and negative operating cash flows in the foreseeable future, as well as potential liquidity to become less than the $2.5 million required under its existing debt covenants during the next twelve months, there exists substantial doubt regarding the Company's ability to continue as a going concern for a period of at least twelve months from the date of issuance of these unaudited condensed consolidated financial statements.”
View the 10-Q filed Aug 11, 2026
Market Cap
$8.64M
Shares
75.34M
Volume · Oct 15 1000 Avg daily vol (3M) 15.75K

EBRCZ metrics

55 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.11
Market cap
$8.64M

Price action

20 metrics
Price change (1W)
-42.7%
Price change (30D)
-49.9%
Price change (3M)
-61.3%
Price change (6M)
-75.9%
Price change (YTD)
-90.4%
Price change (1Y)
-87.9%
Trailing year
Price change (5Y)
—
52-week high
$1.20
52-week low
$0.11
Change from 52-week high
-90.4%
Change from 52-week low
+0.0%
Annualized volatility
240.7%
Annualized volatility (3M)
—
Beta
—
RSI (14D)
31.5
Price vs SMA 50
-63.2%
Price vs SMA 200
—
Avg volume (3M)
15,749
Relative volume
0.1
Average dollar volume
$3,629

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
75.34M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
-5.5×
EV / EBITDA
—
EV / EBIT
—
P / sales
1.3×
reciprocal yield 74.6%
P / book
0.1
reciprocal yield 796.5%
FCF yield
-861.5%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-702.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
14.5%
Operating margin
-2,850.2%
Trailing 12 months
Net margin
-3,015.3%
Gross profit (TTM)
$932,000
Operating profit (TTM)
−$57.74M
Net income (TTM)
−$60.76M
Trailing 12 months
Diluted EPS (TTM)
$-0.27
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.57

Growth

11 metrics
Revenue growth YoY
+1,451.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
$6.45M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+24.4%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-88.2%
Return on assets
-43.8%
Debt / equity
0.6
Current ratio
2.1
EBITDA (TTM)
−$57.09M
Free cash flow (TTM)
−$74.47M
Quick ratio
1.8
Interest coverage
-10.6
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$44.14M
Latest balance sheet
Cash & equivalents
$59.35M
Total assets
$138.68M
Total debt
$41.80M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$65.60M
Capital expenditures (TTM)
$8.88M
R&D (TTM)
$25.61M
SG&A (TTM)
—
Stock compensation (TTM)
$3.69M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1347123 Visit website Investor relations